Expert Discusses Challenges, Risks of Ibrutinib as Chronic Lymphocytic Leukemia Treatment

Name: Expert Discusses Challenges, Risks of Ibrutinib as Chronic Lymphocytic Leukemia Treatment
Uploaded: 2021-12-12T15:31:00.000Z
Description: Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

December 12, 2021

Video

Conference|ASH Annual Meeting and Exposition - American Society of Hematology Annual Meeting and Exposition

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She addressed some of the challenges and risk of ibrutinib treatment for CLL.